Evaluation of limited blood sampling in a preceding 99mTc-labeled diagnostic study to predict the pharmacokinetics and myelotoxicity of 186Re-cMAb U36 radioimmunotherapy

Journal of Nuclear Medicine

Volumn 42, Issue 9, 2001, Pages 1364-1367

  Colnot, D R ^a   Wilhelm, A J ^a   Cloos, J ^a   Roos, J C ^a   De Bree, R ^a   Quak, J J ^a   Snow, G B ^a   Van Dongen, G A M S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dosimetry; Limited sampling model; Monoclonal antibodies; Myelotoxicity; Pharmacokinetics; Radioimmunotherapy

Indexed keywords

CHIMERIC ANTIBODY; MONOCLONAL ANTIBODY U36 RE 186; RHENIUM 186; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; BLOOD SAMPLING; BONE MARROW TOXICITY; CLINICAL ARTICLE; DOSE CALCULATION; DOSIMETRY; DRUG CLEARANCE; FEMALE; HUMAN; ISOTOPE LABELING; MALE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

AGED; ALGORITHMS; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; BAYES THEOREM; BONE MARROW; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOTHERAPY DOSAGE; RECOMBINANT FUSION PROTEINS; REGRESSION ANALYSIS; RHENIUM; THROMBOCYTOPENIA;

EID: 0034847936     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. 131I-labeled anticarcinoembryonic antigen monoclonal antibodies
2. 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck
3. Individualizing drug dosing regimens: Roles of population pharmacokinetic and dynamic models. Bayesian fitting and adaptive control
4. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body
5. 99mTc-labeled monoclonal antibody U36 in patients with head and neck cancer